Market Research Life Sciences Market Research Diagnostics Market Research In Vitro Diagnostics Market Research Coagulation Market Research

Hemophilia Treatment Market By Type (Hemophilia A, Hemophilia B), By Drug Therapy (Recombinant coagulation factor concentrates therapy, Plasma derived coagulation factor concentrates therapy, Non-factor replacement therapy, Others): Global Opportunity Ana

Best Price Guarantee Length Publisher Published Date SKU
from $3,840 198 Pages Allied Market Research June, 2022 ALMR17464504
Best Price Guarantee
Price from $3,840
Length 198 Pages
Publisher Allied Market Research
Published Date June, 2022
SKU ALMR17464504

Hemophilia Treatment Market By Type (Hemophilia A, Hemophilia B), By Drug Therapy (Recombinant coagulation factor concentrates therapy, Plasma derived coagulation factor concentrates therapy, Non-factor replacement therapy, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

The global hemophilia treatment market was valued at $12,764.8 million in 2021, and is projected to reach $26,905.2 million by 2031, registering a CAGR of 7.5% from 2022 to 2031.

Hemophilia is usually an inherited bleeding disorder, in which the blood does not clot properly. This can lead to spontaneous bleeding, followed by injuries or surgery. Blood contains many proteins called clotting factors, which can help stop the bleeding. People with hemophilia have low levels of factor VIII or factor IX. The severity of hemophilia that a person has is determined by the amount of factor in the blood. Hemophilia is caused by a mutation or change, in one of the genes, that provides instructions for making the clotting factor proteins needed to form a blood clot. There are two major types of hemophilia namely, hemophilia A and hemophilia B. The treatment of hemophilia involves replacement of missing blood clotting factor so that the blood can clot properly. This is done by infusion, in which the commercially prepared factor concentrates are administered through a vein. People with hemophilia can learn how to perform these infusions themselves so that they can stop bleeding episodes and, by performing the infusions on a regular basis can even prevent most bleeding episodes.

The major factors that drive the growth of the global hemophilia treatment market include, increase in the prevalence of hemophilia, technological advancements in the treatment of hemophilia, and favorable government initiatives for hemophilia management. In addition, increase in target population, increased diagnosis rate, and rise in the use of prophylactic treatment for hemophilia also propel the market growth. However, high cost of hemophilia treatment, lack of medicines of hemophilia, and serious adverse effects associated with plasma derived products are expected to restrict the market growth. Conversely, the rise in the awareness about hemophilia in developing countries provides lucrative opportunities for the growth of the market.

The hemophilia treatment market is segmented on the basis of type, drug therapy, and region. According to type, the market is divided into hemophilia A and hemophilia B. On the basis of drug therapy, the market is bifurcated into recombinant coagulation factor concentrates therapy, plasma derived coagulation factor concentrates therapy, non-factor replacement therapy, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include, Bayer AG, Pfizer, Inc., F. Hoffmann-La Roche AG, CSL Ltd., Takeda Pharmaceuticals Company Ltd., Novo Nordisk A/S, Grifols S.A., Swedish Orphan Biovitrium AB, Octapharma AG, and Medexus Pharmaceuticals Inc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hemophilia treatment market analysis from 2021 to 2031 to identify the prevailing hemophilia treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hemophilia treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hemophilia treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

Hemophilia A
Hemophilia B

By Drug Therapy

Recombinant coagulation factor concentrates therapy
Plasma derived coagulation factor concentrates therapy
Non-factor replacement therapy
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa,
Saudi Arabia
Rest of LAMEA

Key Market Players

Bayer AG
CSL Ltd. (CSL Behring)
F. Hoffmann-La Roche AG
Grifols, S.A
Medexus Pharmaceuticals Inc.
Novo Nordisk A/S
octapharma ag
Pfizer Inc.
Swedish Orphan Biovitrum AB
Takeda Pharmaceuticals Company ltd

Please Note: It will take 7-10 business days to complete the report upon order confirmation.


CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: HEMOPHILIA TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Hemophilia A
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Hemophilia B
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY
5.1 Overview
5.1.1 Market size and forecast
5.2 Recombinant coagulation factor concentrates therapy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Plasma derived coagulation factor concentrates therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Non-factor replacement therapy
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Others
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
CHAPTER 6: HEMOPHILIA TREATMENT MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Type
6.2.3 North America Market size and forecast, by Drug Therapy
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Type
6.2.4.1.2 Market size and forecast, by Drug Therapy
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Type
6.2.4.2.2 Market size and forecast, by Drug Therapy
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Type
6.2.4.3.2 Market size and forecast, by Drug Therapy
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Type
6.3.3 Europe Market size and forecast, by Drug Therapy
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Type
6.3.4.1.2 Market size and forecast, by Drug Therapy
6.3.4.2 France
6.3.4.2.1 Market size and forecast, by Type
6.3.4.2.2 Market size and forecast, by Drug Therapy
6.3.4.3 U.K.
6.3.4.3.1 Market size and forecast, by Type
6.3.4.3.2 Market size and forecast, by Drug Therapy
6.3.4.4 Italy
6.3.4.4.1 Market size and forecast, by Type
6.3.4.4.2 Market size and forecast, by Drug Therapy
6.3.4.5 Spain
6.3.4.5.1 Market size and forecast, by Type
6.3.4.5.2 Market size and forecast, by Drug Therapy
6.3.4.6 Rest of Europe
6.3.4.6.1 Market size and forecast, by Type
6.3.4.6.2 Market size and forecast, by Drug Therapy
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Type
6.4.3 Asia-Pacific Market size and forecast, by Drug Therapy
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Market size and forecast, by Type
6.4.4.1.2 Market size and forecast, by Drug Therapy
6.4.4.2 China
6.4.4.2.1 Market size and forecast, by Type
6.4.4.2.2 Market size and forecast, by Drug Therapy
6.4.4.3 Australia
6.4.4.3.1 Market size and forecast, by Type
6.4.4.3.2 Market size and forecast, by Drug Therapy
6.4.4.4 India
6.4.4.4.1 Market size and forecast, by Type
6.4.4.4.2 Market size and forecast, by Drug Therapy
6.4.4.5 South Korea
6.4.4.5.1 Market size and forecast, by Type
6.4.4.5.2 Market size and forecast, by Drug Therapy
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Market size and forecast, by Type
6.4.4.6.2 Market size and forecast, by Drug Therapy
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Type
6.5.3 LAMEA Market size and forecast, by Drug Therapy
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Type
6.5.4.1.2 Market size and forecast, by Drug Therapy
6.5.4.2 South Africa,
6.5.4.2.1 Market size and forecast, by Type
6.5.4.2.2 Market size and forecast, by Drug Therapy
6.5.4.3 Saudi Arabia
6.5.4.3.1 Market size and forecast, by Type
6.5.4.3.2 Market size and forecast, by Drug Therapy
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Market size and forecast, by Type
6.5.4.4.2 Market size and forecast, by Drug Therapy
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Bayer AG
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 CSL Ltd. (CSL Behring)
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 F. Hoffmann-La Roche AG
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Grifols, S.A
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Medexus Pharmaceuticals Inc.
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Novo Nordisk A/S
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 octapharma ag
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Pfizer Inc.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Swedish Orphan Biovitrum AB
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Takeda Pharmaceuticals Company ltd
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 2. HEMOPHILIA TREATMENT MARKET REVENUE, FOR HEMOPHILIA A, BY REGION , 2021-2031,($MILLION)
TABLE 3. HEMOPHILIA TREATMENT MARKET FOR HEMOPHILIA A BY COUNTRY, 2021-2031,($MILLION)
TABLE 4. HEMOPHILIA TREATMENT MARKET REVENUE, FOR HEMOPHILIA B, BY REGION , 2021-2031,($MILLION)
TABLE 5. HEMOPHILIA TREATMENT MARKET FOR HEMOPHILIA B BY COUNTRY, 2021-2031,($MILLION)
TABLE 6. GLOBAL HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 7. HEMOPHILIA TREATMENT MARKET REVENUE, FOR RECOMBINANT COAGULATION FACTOR CONCENTRATES THERAPY, BY REGION , 2021-2031,($MILLION)
TABLE 8. HEMOPHILIA TREATMENT MARKET FOR RECOMBINANT COAGULATION FACTOR CONCENTRATES THERAPY BY COUNTRY, 2021-2031,($MILLION)
TABLE 9. HEMOPHILIA TREATMENT MARKET REVENUE, FOR PLASMA DERIVED COAGULATION FACTOR CONCENTRATES THERAPY, BY REGION , 2021-2031,($MILLION)
TABLE 10. HEMOPHILIA TREATMENT MARKET FOR PLASMA DERIVED COAGULATION FACTOR CONCENTRATES THERAPY BY COUNTRY, 2021-2031,($MILLION)
TABLE 11. HEMOPHILIA TREATMENT MARKET REVENUE, FOR NON-FACTOR REPLACEMENT THERAPY, BY REGION , 2021-2031,($MILLION)
TABLE 12. HEMOPHILIA TREATMENT MARKET FOR NON-FACTOR REPLACEMENT THERAPY BY COUNTRY, 2021-2031,($MILLION)
TABLE 13. HEMOPHILIA TREATMENT MARKET REVENUE, FOR OTHERS, BY REGION , 2021-2031,($MILLION)
TABLE 14. HEMOPHILIA TREATMENT MARKET FOR OTHERS BY COUNTRY, 2021-2031,($MILLION)
TABLE 15. HEMOPHILIA TREATMENT MARKET, BY REGION, 2021-2031,($MILLION)
TABLE 16. NORTH AMERICA HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 17. NORTH AMERICA HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 18. NORTH AMERICA HEMOPHILIA TREATMENT MARKET, BY COUNTRY, 2021-2031,($MILLION)
TABLE 19. U.S. HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 20. U.S. HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 21. CANADA HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 22. CANADA HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 23. MEXICO HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 24. MEXICO HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 25. EUROPE HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 26. EUROPE HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 27. EUROPE HEMOPHILIA TREATMENT MARKET, BY COUNTRY, 2021-2031,($MILLION)
TABLE 28. GERMANY HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 29. GERMANY HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 30. FRANCE HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 31. FRANCE HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 32. U.K. HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 33. U.K. HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 34. ITALY HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 35. ITALY HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 36. SPAIN HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 37. SPAIN HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 38. REST OF EUROPE HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 39. REST OF EUROPE HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 40. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 41. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 42. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET, BY COUNTRY, 2021-2031,($MILLION)
TABLE 43. JAPAN HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 44. JAPAN HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 45. CHINA HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 46. CHINA HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 47. AUSTRALIA HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 48. AUSTRALIA HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 49. INDIA HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 50. INDIA HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 51. SOUTH KOREA HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 52. SOUTH KOREA HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 53. REST OF ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 54. REST OF ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 55. LAMEA HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 56. LAMEA HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 57. LAMEA HEMOPHILIA TREATMENT MARKET, BY COUNTRY, 2021-2031,($MILLION)
TABLE 58. BRAZIL HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 59. BRAZIL HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 60. SOUTH AFRICA, HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 61. SOUTH AFRICA, HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 62. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 63. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 64. REST OF LAMEA HEMOPHILIA TREATMENT MARKET, BY TYPE, 2021-2031,($MILLION)
TABLE 65. REST OF LAMEA HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY, 2021-2031,($MILLION)
TABLE 66.BAYER AG: COMPANY SNAPSHOT
TABLE 67.BAYER AG: OPERATING SEGMENTS
TABLE 68.BAYER AG: PRODUCT PORTFOLIO
TABLE 69.BAYER AG: NET SALES,
TABLE 70.BAYER AG: KEY STRATERGIES
TABLE 71.CSL LTD. (CSL BEHRING): COMPANY SNAPSHOT
TABLE 72.CSL LTD. (CSL BEHRING): OPERATING SEGMENTS
TABLE 73.CSL LTD. (CSL BEHRING): PRODUCT PORTFOLIO
TABLE 74.CSL LTD. (CSL BEHRING): NET SALES,
TABLE 75.CSL LTD. (CSL BEHRING): KEY STRATERGIES
TABLE 76.F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 77.F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
TABLE 78.F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 79.F. HOFFMANN-LA ROCHE AG: NET SALES,
TABLE 80.F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
TABLE 81.GRIFOLS, S.A: COMPANY SNAPSHOT
TABLE 82.GRIFOLS, S.A: OPERATING SEGMENTS
TABLE 83.GRIFOLS, S.A: PRODUCT PORTFOLIO
TABLE 84.GRIFOLS, S.A: NET SALES,
TABLE 85.GRIFOLS, S.A: KEY STRATERGIES
TABLE 86.MEDEXUS PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 87.MEDEXUS PHARMACEUTICALS INC.: OPERATING SEGMENTS
TABLE 88.MEDEXUS PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 89.MEDEXUS PHARMACEUTICALS INC.: NET SALES,
TABLE 90.MEDEXUS PHARMACEUTICALS INC.: KEY STRATERGIES
TABLE 91.NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 92.NOVO NORDISK A/S: OPERATING SEGMENTS
TABLE 93.NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 94.NOVO NORDISK A/S: NET SALES,
TABLE 95.NOVO NORDISK A/S: KEY STRATERGIES
TABLE 96.OCTAPHARMA AG: COMPANY SNAPSHOT
TABLE 97.OCTAPHARMA AG: OPERATING SEGMENTS
TABLE 98.OCTAPHARMA AG: PRODUCT PORTFOLIO
TABLE 99.OCTAPHARMA AG: NET SALES,
TABLE 100.OCTAPHARMA AG: KEY STRATERGIES
TABLE 101.PFIZER INC.: COMPANY SNAPSHOT
TABLE 102.PFIZER INC.: OPERATING SEGMENTS
TABLE 103.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 104.PFIZER INC.: NET SALES,
TABLE 105.PFIZER INC.: KEY STRATERGIES
TABLE 106.SWEDISH ORPHAN BIOVITRUM AB: COMPANY SNAPSHOT
TABLE 107.SWEDISH ORPHAN BIOVITRUM AB: OPERATING SEGMENTS
TABLE 108.SWEDISH ORPHAN BIOVITRUM AB: PRODUCT PORTFOLIO
TABLE 109.SWEDISH ORPHAN BIOVITRUM AB: NET SALES,
TABLE 110.SWEDISH ORPHAN BIOVITRUM AB: KEY STRATERGIES
TABLE 111.TAKEDA PHARMACEUTICALS COMPANY LTD: COMPANY SNAPSHOT
TABLE 112.TAKEDA PHARMACEUTICALS COMPANY LTD: OPERATING SEGMENTS
TABLE 113.TAKEDA PHARMACEUTICALS COMPANY LTD: PRODUCT PORTFOLIO
TABLE 114.TAKEDA PHARMACEUTICALS COMPANY LTD: NET SALES,
TABLE 115.TAKEDA PHARMACEUTICALS COMPANY LTD: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.HEMOPHILIA TREATMENT MARKET SEGMENTATION
FIGURE 2.HEMOPHILIA TREATMENT MARKET,2021-2031
FIGURE 3.HEMOPHILIA TREATMENT MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.HEMOPHILIA TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.HEMOPHILIA TREATMENT MARKET,BY TYPE,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF HEMOPHILIA A HEMOPHILIA TREATMENT MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF HEMOPHILIA B HEMOPHILIA TREATMENT MARKET,2021-2031(%)
FIGURE 15.HEMOPHILIA TREATMENT MARKET,BY DRUG THERAPY,2021(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF RECOMBINANT COAGULATION FACTOR CONCENTRATES THERAPY HEMOPHILIA TREATMENT MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF PLASMA DERIVED COAGULATION FACTOR CONCENTRATES THERAPY HEMOPHILIA TREATMENT MARKET,2021-2031(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF NON-FACTOR REPLACEMENT THERAPY HEMOPHILIA TREATMENT MARKET,2021-2031(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF OTHERS HEMOPHILIA TREATMENT MARKET,2021-2031(%)
FIGURE 20.HEMOPHILIA TREATMENT MARKET BY REGION,2021
FIGURE 21.U.S. HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 22.CANADA HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 23.MEXICO HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 24.GERMANY HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 25.FRANCE HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 26.U.K. HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 27.ITALY HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 28.SPAIN HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 29.REST OF EUROPE HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 30.JAPAN HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 31.CHINA HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 32.AUSTRALIA HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 33.INDIA HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 34.SOUTH KOREA HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 35.REST OF ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 36.BRAZIL HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 37.SOUTH AFRICA, HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 38.SAUDI ARABIA HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 39.REST OF LAMEA HEMOPHILIA TREATMENT MARKET,2021-2031($MILLION)
FIGURE 40. TOP WINNING STRATEGIES, BY YEAR
FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 43.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 44.COMPETITIVE DASHBOARD
FIGURE 45.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 46.BAYER AG.: NET SALES ,($MILLION)
FIGURE 47.CSL LTD. (CSL BEHRING).: NET SALES ,($MILLION)
FIGURE 48.F. HOFFMANN-LA ROCHE AG.: NET SALES ,($MILLION)
FIGURE 49.GRIFOLS, S.A.: NET SALES ,($MILLION)
FIGURE 50.MEDEXUS PHARMACEUTICALS INC..: NET SALES ,($MILLION)
FIGURE 51.NOVO NORDISK A/S.: NET SALES ,($MILLION)
FIGURE 52.OCTAPHARMA AG.: NET SALES ,($MILLION)
FIGURE 53.PFIZER INC..: NET SALES ,($MILLION)
FIGURE 54.SWEDISH ORPHAN BIOVITRUM AB.: NET SALES ,($MILLION)
FIGURE 55.TAKEDA PHARMACEUTICALS COMPANY LTD.: NET SALES ,($MILLION)

$5,769
$3,840
$6,450
$10,995

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings